The Scientific and Research Institute of Experimental Medicine (IEM) and the BIOCAD company are conducting preclinical studies of a binary vaccine against seasonal influenza and coronavirus, IEM Director Alexander Dmitriev said, RIA Novosti reports.
He noted that the trials would be completed soon.
The binary action vaccine is a joint development of the IEM and BIOCAD company. We are at the stage of preclinical studies and, I hope, we will complete them very soon, Dmitriev added.
At a press conference held online, the director of the IEM clarified that this vaccine is available in the form of drops, which makes it easier for children to use.
NEWS.ru reported earlier that the US pharmaceutical company Pfizer, which has developed a vaccine against coronavirus, warned Washington that the drug might not be enough to implement the US plan to vaccinate the country’s population, the Washington Post reports.